Nuvation Bio Inc. (NUVB) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Nuvation Bio Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:05.439 Good afternoon, and welcome to the NovationBio first quarter 2025 financial results 00:00:05.439 -- 00:00:09.865 and business update conference call. Please be advised that today's conference call is 00:00:09.865 -- 00:00:14.511 being recorded. At this time, all participants are in a listen-only mode. 00:00:14.511 -- 00:00:18.096 Following the formal remarks, we will open the call for questions. 00:00:18.096 -- 00:00:19.919 I would now like to turn the call over to J.R. 00:00:19.919 -- 00:00:25.126 DeVita, Executive Director of Corporate Development and Investor Relations at NovationBio. 00:00:25.126 -- 00:00:27.587 Please go ahead. 00:00:27.930 -- 00:00:32.934 Thank you, and good afternoon, everyone. Joining me on today's call are Dr. 00:00:32.934 -- 00:00:38.722 David Hung, our founder, president, and chief executive officer, Colleen Sjogren, 00:00:38.722 -- 00:00:45.672 our chief commercial officer, and Philippe Sauvage, our chief financial officer. 00:00:45.672 -- 00:00:49.598 Certain statements we make during this call will be forward-looking. 00:00:49.598 -- 00:00:54.906 These include statements about talent directives, expected FDA approval, 00:00:54.906 -- 00:01:00.229 U.S. commercial launch, and potential benefit for patients, our commercial teams launch 00:01:00.229 -- 00:01:03.955 readiness, and our cash runway. 00:01:03.955 -- 00:01:09.324 Because such statements deal with future events that are subject to many risks and uncertainties, 00:01:09.324 -- 00:01:15.334 actual results may differ materially from those in the forward-looking statements. 00:01:15.334 -- 00:01:21.283 For a full discussion of these risks and uncertainties, please review our annual report 00:01:21.283 -- 00:01:26.631 on Form 10-K and our quarterly ...